Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Fineline Cube Feb 28, 2026
Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Fineline Cube Feb 28, 2026
Company Deals Digital

Pica Partners with BrainCo to Launch ADHD Product in China

Fineline Cube Aug 1, 2022

Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with...

Hospital Policy / Regulatory

NHC Designates National Mental Illness Medical Centers in Beijing and Shanghai

Fineline Cube Aug 1, 2022

The National Healthcare Commission (NHC) announced the establishment of national mental illness medical centers, designating...

Company Drug

Innovent and Laekna Dose First Patient in Afuresertib and Tyvyt Study for PD-1 Resistant Tumors

Fineline Cube Aug 1, 2022

China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that...

Company Drug

Dongcheng Pharmaceutical Gets NMPA Green Light for PSMA PET Imaging Drug

Fineline Cube Aug 1, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced it has received approval from...

Company Drug

CanSino Biologics Launches Menhycia Meningococcal Vaccine in Six Provinces

Fineline Cube Aug 1, 2022

China-based CanSino Biologics (HKG: 6185) announced the launch of its ACYW135 Meningococcal Conjugate Vaccine (CRM197)...

Company Drug

Mabwell Bioscience Gets FDA Approval for Nectin-4 ADC 9MW2821 in Solid Tumors

Fineline Cube Aug 1, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received approval from the...

Company Drug

LaNova Medicines Gets FDA Green Light for LM-305 Myeloma Study

Fineline Cube Aug 1, 2022

Shanghai-based cancer therapy developer LaNova Medicines Ltd announced it has received approval from the U.S....

Company

Sanofi’s Q2 Earnings Show 8.1% Global Sales Growth, Led by Dupixent and China Expansion

Fineline Cube Jul 29, 2022

France-based Sanofi (NASDAQ: SNY) reported Q2 2022 global sales of EUR 10.1 billion (USD 10.3...

Company Drug

CSPC Pharmaceutical’s Albumin-Bound Docetaxel Receives Orphan Drug Designation for Gastric Cancer

Fineline Cube Jul 29, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received an orphan drug...

Drug

Hybio Pharmaceutical’s Liraglutide Filing Accepted by NMPA, Becomes Domestic Leader in GLP-1 Analog

Fineline Cube Jul 29, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its market filing for liraglutide, a...

Drug

Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors

Fineline Cube Jul 29, 2022

Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical...

Company Drug

Kira Pharmaceuticals’ KP104 Receives Orphan Drug Designation for PNH Treatment

Fineline Cube Jul 29, 2022

Sino-US biotech Kira Pharmaceuticals announced that it has received an Orphan Drug Designation (ODD) from...

Policy / Regulatory R&D

Shenzhen Unveils Measures to Boost Biomedical and Medical Device Industries

Fineline Cube Jul 29, 2022

Shenzhen’s municipal Development and Reform Commission has released a series of measures to promote the...

Company

Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth

Fineline Cube Jul 29, 2022

US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD...

Company Drug

Takeda’s Alunbrig Prescribed in China for ALK+ NSCLC Treatment

Fineline Cube Jul 29, 2022

Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502) announced that its lung cancer therapy Alunbrig (brigatinib)...

Company Deals

Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio

Fineline Cube Jul 29, 2022

Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China’s 3SBio Inc. (HKG: 1530) have signed a...

Company R&D

PerkinElmer and SCUT Launch Joint Translational Medicine Center

Fineline Cube Jul 29, 2022

US-based PerkinElmer and China’s South China University of Technology (SCUT) have officially launched their joint...

Policy / Regulatory

Sun Pharma’s Bicalutamide Supply Suspended in Multiple Chinese Regions

Fineline Cube Jul 28, 2022

India-based Sun Pharma has suspended the supply of its bicalutamide to Beijing, Tianjin, Jilin, Shanghai,...

Company Drug

MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study

Fineline Cube Jul 28, 2022

Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...

Company Deals

CSPC Jushi Biopharm’s SYSA1801 ADC Secures Licensing Deal with Elevation Oncology

Fineline Cube Jul 28, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary, CSPC Jushi Biopharmaceutical Co.,...

Posts pagination

1 … 605 606 607 … 628

Recent updates

  • Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion
  • Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA
  • Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer
  • Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis
  • Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Company Drug

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Company Drug

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.